UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	, FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/514,626	06/23/2005	Finn Skou Pedersen	PEDERSEN10	7989
BROWDY AND NEIMARK, P.L.L.C. 624 NINTH STREET, NW			EXAMINER	
			PENG, BO	
SUITE 300	N, DC 20001-5303		ART UNIT	PAPER NUMBER
Whomitton, 50 20001 3303			1648	
			MAIL DATE	DELIVERY MODE
			10/05/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

- F	Lauren No	Anglicant(a)				
	Application No.	Applicant(s)				
	10/514,626	PEDERSEN ET AL.				
Office Action Summary	Examiner	Art Unit				
	Bo Peng	1648				
The MAILING DATE of this communication app Period for Reply	pears on the cover sheet with the c	orrespondence address				
A SHORTENED STATUTORY PERIOD FOR REPL' WHICHEVER IS LONGER, FROM THE MAILING D. Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period of Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be timwill apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE	N. sely filed the mailing date of this communication. D (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on 22 C	october 2004.					
,						
Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
closed in accordance with the practice under E	=x parte Quayle, 1935 C.D. 11, 45	53 O.G. 213.				
Disposition of Claims		•				
4) ⊠ Claim(s) 1,4,6-19,21,22,24,27-33,35-37,39 an 4a) Of the above claim(s) 28 is/are withdrawn f 5) □ Claim(s) is/are allowed. 6) □ Claim(s) is/are rejected. 7) □ Claim(s) is/are objected to. 8) ⊠ Claim(s) 1, 4, 6-19, 21, 22, 24, 27, 28-33, 35-3	from consideration.	,				
Application Papers						
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) acc Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Examine 11.	epted or b) objected to by the l drawing(s) be held in abeyance. See tion is required if the drawing(s) is ob	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).				
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.						
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Do 5) Notice of Informal F 6) Other:	ate				

Application/Control Number: 10/514,626 Page 2

Art Unit: 1648

DETAILED ACTION

1. The Office acknowledges the application filed on October 22, 2004. Claims 2, 3, 5, 20, 23, 25, 26, 34, 38 and 41 are cancelled. Claims 1, 4, 6-19, 21, 22, 24, 27-33, 35-37, 39 and 40 are pending.

- 2. <u>Note: The examiner encourages a prompt response to Election/Restrictions to expedite</u> the prosecution of this case. Applicant is reminded that any amendment should compliant with the Claims and Continuations Final Rule, which becomes effective on November 1, 2007. The new rules have been published in the Federal Register 46716, Vol. 72, No. 161, August 2007, and also are available at USPTO website.
- 3. It is noted that Claim 28 depends on cancelled Claim 26. Claim 28 has not been grouped with any invention because it is not clear what is being claimed.

Election/Restrictions

- 4. Restriction is required under 35 U.S.C. 121 and 372.
- 5. This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1, 4, 6-19, 21, 22, 24, 27, 29 and 30 drawn to products and the first claimed method of using the products.

Group II, claim(s) 31 drawn to the second claimed method of using the products.

Group III, claim 32, drawn to the third claimed method of using the products.

Group IV, claim 33, drawn to the fourth claimed method of using the products.

Group V, claim 35-37, 39 and 40, drawn to the fifth claimed method of using the products.

Application/Control Number: 10/514,626 Page 3

Art Unit: 1648

6. The first recited method of using the claimed products will be examined together with the products, in accordance with 37 CFR 1.475(d).

Species Election

- 7. This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.
- 8. The species are as follows:
 - (1) A purified retroviral env peptide of Claims 1, 4 and 6-10);
 - (2) A purified retroviral env peptide of Claims 1, 4 and 11-13);
 - (3) A purified retroviral env peptide of Claims 1, 4, 14 and 15);
 - (4) A recombinant mammalian cell displaying an env peptide (Claim 16);
 - (5) An isolated nucleic acid or vector (Claims 17-19, 27, 29); and
 - (6) Replication competent retrovirus (Claims 21, 22 and 24)
- 9. The claims recite an undetermined number of polypeptides which are described in terms of their functional characteristics, rather than their physical structure. It is not clear what the common structural element is which is responsible for the recited functional characteristics, given that the claims encompass sequence variants and fragments. Moreover, more than one function is recited in claim 4.
- 10. All claims are generic with the exception of claim 18.
- 11. No matter which invention is elected, Applicant is required, in reply to this action, to elect a single species (polypeptide sequence) to which the claims shall be restricted if no generic claim is finally held to be allowable. The reply must also identify the claims readable on

•

Application/Control Number: 10/514,626 Page 4

Art Unit: 1648

the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

- 12. Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).
- 13. Applicant is advised that the reply to this requirement to be complete <u>must</u> include (i) an election of a invention to be examined even though the requirement may be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.
- 10. The election of an invention may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse. Traversal must be presented at the time of election in order to be considered timely. Failure to timely traverse the requirement will result in the loss of right to petition under 37 CFR 1.144. If claims are added after the election, applicant must indicate which of these claims are readable on the elected invention.
- 14. If claims are added after the election, applicant must indicate which of these claims are readable upon the elected invention.
- 15. Should applicant traverse on the ground that the inventions are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.
- 16. The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. Process claims that depend from or otherwise include all the limitations of the patentable product will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.
- 17. In the event of rejoinder, the requirement for restriction between the product claims and the

Application/Control Number: 10/514,626

Art Unit: 1648

rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of *In re Ochiai, In re Brouwer* and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

18. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Bo Peng, Ph.D. whose telephone number is 571-272-5542. The examiner can normally be reached on M-F, 9-5:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Bruce Campell, Ph.D. can be reached on 571-272-0974. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Bo Peng, Ph.D. September 20, 2007

/Bruce Campell/ Supervisory Patent Examiner Art Unit 1648